Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Impax Laboratories Inc    IPXL

News SummaryMost relevantAll newsSector newsTweets

Impax Laboratories Inc : Impax Laboratories to Present at the UBS Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
05/20/2013 | 01:35pm CET

Impax Laboratories, Inc. (NASDAQ: IPXL) today announced that the Company will present at the UBS Global Healthcare Conference on Wednesday, May 22, at 9:00 a.m. Eastern Standard Time. The conference will be held at the Sheraton New York Hotel.

Individuals may listen to the live or an archived presentation made at the conference, which will be posted in the investor relations section of the Company's web site at www.impaxlabs.com. This presentation will be archived on the Company's web site for 30 days.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. (Impax) is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams and ointments. For more information, please visit the Company's Web site at: www.impaxlabs.com.

Impax Laboratories, Inc.
Mark Donohue, 215-558-4526
Investor Relations and Corporate Communications

© Business Wire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
11/10 IMPAX LABORATORIES : Announces Successful Completion of Consent Solicitation wit..
11/09 IMPAX LABORATORIES : Management's Discussion and Analysis of Results of Operatio..
11/09 IMPAX LABORATORIES : Labs reports 3Q loss
11/09 IMPAX LABORATORIES INC : Results of Operations and Financial Condition, Regulati..
11/09 IMPAX LABORATORIES : Reports Third Quarter 2017 Results
11/09 IMPAX LABORATORIES INC : Impax Laboratories, Inc. to Host Earnings Call
11/08 IMPAX LABORATORIES : Mourns the Passing of Board Member Richard A. Bierly
11/07 IMPAX LABORATORIES INC : Entry into a Material Definitive Agreement, Regulation ..
11/07 IMPAX LABORATORIES : Announces Successful Completion of Consent Solicitation wit..
11/02 IMPAX LABORATORIES : Wolf Popper LLP Investigates the Proposed Acquisition of Im..
More news
News from SeekingAlpha
11/13 Impax Laboratories, Inc. 2017 Q3 - Results - Earnings Call Slides
11/09 Impax Laboratories (IPXL) Q3 2017 Results - Earnings Call Transcript
11/09 Impax Lab beats by $0.03, misses on revenue
11/08 Notable earnings before Thursday?s open
11/06 Generics up on Mylan sales forecast and potential $3B investment in Teva by n..
Financials ($)
Sales 2017 792 M
EBIT 2017 96,2 M
Net income 2017 -44,5 M
Debt 2017 631 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018 22,95
EV / Sales 2017 2,36x
EV / Sales 2018 2,57x
Capitalization 1 236 M
Duration : Period :
Impax Laboratories Inc Technical Analysis Chart | IPXL | US45256B1017 | 4-Traders
Technical analysis trends IMPAX LABORATORIES INC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 13
Average target price 20,2 $
Spread / Average Target 21%
EPS Revisions
Paul M. Bisaro President, Chief Executive Officer & Director
Robert L. Burr Chairman
Andrew Schaschl Senior Vice President-Global Operations
Bryan M. Reasons Chief Financial Officer & Senior VP-Finance
Jeffrey D. Nornhold Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON20.74%373 077
NOVARTIS10.73%218 225
PFIZER8.87%211 963
ROCHE HOLDING LTD.-2.06%200 423
MERCK AND COMPANY-6.91%150 468